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ABSTRACT 
Menopause is reported to be associated with increased urinary calcium excretion, which may enhance the risk for 
the development of calcium kidney stones. However, it remains controversial about whether high level of post-
menopausal hormone (PMH) is a risk factor for formation of nephrolithiasis. Several observational studies have 
shown that PMH is protective based on 24-hour urinary parameters. Recent clinical trials provided evidence to 
conclude that estrogen therapy increases the risk of nephrolithiasis in healthy postmenopausal women. Our study 
aimed to comprehensively assess clinical evidence on the relationship between postmenopausal hormone level and 
risk of nephrolithiasis. To conduct systematic review, we pooled total 98 potentially related articles in Cochrane 
library, Medline, and Embase. Three studies with a total of 71101 study participants that included two clinical 
trials, 4 stratified and potentially usable results by the status of menopause and type of PMH use derived from one 
prospective cohort study, and one case-control studies were selected to pool relative risk using random-effect 
model. How the difference in menopause status, whether naturally menopausal or surgically menopausal, influ-
enced the pooled relative risk was included in the subgroup analysis. The study population aged from 45 to 70 
years old. The follow-up year and adjusted confounders differed across different studies. The pooled relative risk 
for the 7 stratified studies was 0.91 (95 % confidence interval (CI): [0.72, 1.14]). In the menopausal status-specific 
analysis, the pooled relative risk for naturally menopausal women was 0.92 (95 % CI, [0.64, 1.27]; I2 = 82.74 %) 
whereas the pooled relative risk for surgically postmenopausal women is 0.90 (95 % CI, [0.63, 1.29]; I2 = 78.47 %). 
The above results suggested that there was no significant association between PMH and the risk of nephrolithiasis. 
The difference in menopausal status did not influence the relationship between PMH and the risk of kidney stone 
formation.  
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INTRODUCTION 
Nephrolithiasis (kidney stone) is a com-
mon disease among postmenopausal women, 
affecting around 5 %-7 % of the population in 
the United States (Novak et al., 2009). A 
sharp increase in urinary calcium stone for-
mation after menopause implies a close corre-
lation between hormone level and pathology 
of nephrolithiasis. Estrogen replacement, 
which is aimed at relieving symptoms of men-
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opause, increased citrate and calcium excre-
tion in rates in postmenopausal women with 
recurrent urolithiasis (Dey et al., 2002). The 
increased stone inhibitory citrate level and in-
creased agglomeration inhibition by estrogen 
replacement implied an overall beneficial and 
protective effect of estrogen on the risk of cal-
cium oxalate stone formation in postmeno-
pausal women (Iguchi et al., 1999). However, 
recent studies found that hormone use such as 
estrogen replacement therapy among healthy 
women may be associated with a higher risk 
of nephrolithiasis (Maalouf et al., 2010; 
Mattix Kramer et al., 2003). The seemly-con-
flicted results may be due to the diverse nature 
of studies conducted in order to investigate 
how hormone is associated with the risk of 
kidney stone formation. Different cohort sam-
ples may also contribute to differences in the 
results. To the best of our knowledge, there is 
very few systematic review on hormone use 
and the risk of nephrolithiasis among healthy 
postmenopausal women. Here we conducted 
a systematic review and prospective meta-
analysis on several observational studies and 
clinical trials to examine whether the 
postmenopausal hormone is a risk factor for 
kidney stone formation. We aimed at explor-
ing the true effect of PMH on the risk of inci-
dent kidney stones. 
 
MATERIAL AND METHODS 
Searching strategy and selection criteria 
Literature searching was performed by us-
ing Cochrane library, Medline, and Embase. 
The searching terms included combinations 
of keywords and their synonyms, such as 
“Nephrolithiasis”, “postmenopausal”, “Estro-
gen”, “kidney stone”, “renal lithiasis”, “renal 
stone”, “women”, “observational”, and “Clin-
ical Trials”. And the search strategies used for 
the other databases were similar, with the nec-
essary adaptions made. Additionally, we 
manually searched reference lists in the se-
lected studies to identify potentially relevant 
studies. 
 
Study selection and data extraction 
We set up the inclusion and exclusion cri-
teria to include eligible studies. We focused 
on postmenopausal women aged around 45 to 
79 years with no previous history of kidney 
stones and selected cohort studies that com-
pared the risk of kidney stones among the 
group with PMH treatment and the group 
without. The estimated values of odds ratio 
(OR), relative risk (RR) or hazard ratio (HR) 
and its 95 % confidence interval (CI) needed 
to be specifically reported. Demographic 
characteristics such as age, sex, body mass in-
dex (BMI), serum calcium, and urinary cal-
cium were described. Confounders such as 
age were adjusted if necessary. The exclusion 
criteria included: (1) only age-adjusted or 
other confounder-adjusted OR, RR, or HR 
were reported. (2) The subjects of the study 
had recurrent nephrolithiasis or other signifi-
cant chronic kidney diseases. (3) The data 
were extracted from the same study popula-
tion. After carefully reviewing the selected 
studies, the following information on the pub-
lications was collected: abstract, full text, ti-
tle, author information (i.e. first name, last 
name, initials), and publication year. Charac-
teristics included country of origin, sample 
size, age, follow-up time, type of risks and 
confounders-adjusted risks were extracted 
from the selected studies.  
 
Statistical analyses 
Multivariate-adjusted outcome data (ORs, 
RRs, HRs and 95 % CI) were extracted and 
converted logarithmically to log (RR) for 
each study. The I-squared statistic was used 
for heterogeneity test, and the log (RR) of the 
studies were pooled using fixed effect models 
when the heterogeneity is low (i.e., I-squared 
< 30%). Otherwise, a random effect model 
was used. Forest plots were constructed to 
visually demonstrate RRs and their confi-
dence interval. Funnel plot was constructed 
after Trim-and-Hill correction for evaluating 
funnel asymmetry. Fail-safe N was used to 
determine the number of NULL studies that 
have to be added to reduce the significance of 
the meta-analysis to (0.05). Publication bias 
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was analyzed by using Egger’s regression 
test. The sensitivity analyses were conducted 
by omitting one study at a time to recalculate 
the pooled RR. All above analyses were per-
formed by R version 3.3.2 with functional 
packages including ggplot2, metafor, rmeta, 
and meta. 
 
RESULTS 
Literature search 
A total of 98 potentially related articles 
were identified after employing the searching 
strategy in Medline (PubMed), Embase, and 
Cochrane library. 76 duplicated articles or 
non-research type’s articles or non-English 
written articles were removed after screening 
their titles and abstracts. The remaining 22 ar-
ticles were carefully reviewed by several in-
dependent reviewers. The selection process 
was demonstrated as shown in Figure 1. 
 
Study characteristics 
Three studies including one clinical study, 
one prospective cohort study, and case-con-
trol study were included in the meta-analysis. 
The characteristics of publications and their 
included demographics were summarized as 
shown in Table 1. Two studies were con-
ducted in the United States and one case-con-
trol study was conducted in China. The study 
population was aimed at postmenopausal 
women with natural or surgical menopause 
and matched-up controls. Mattix Kramer et al. 
(2003) studied on postmenopausal women 
with 26,251 undergoing natural menopause 
and 17,306 undergoing surgical menopause: 
mean age and BMI of natural postmenopausal 
females were 60.4 years old and 25.7 kg/m2, 
while mean age and BMI of surgical 
postmenopausal females were 58.3 and 25.8. 
The study by Maalouf et al. (2010) contains 
two clinical trials: 10,739 postmenopausal 
women with hysterectomy were enrolled in 
the estrogen-alone trial, while 16,608 post-
menopausal women without hysterectomy 
were enrolled in the estrogen plus progestin 
(E+P) trial. Women in the estrogen-alone trial 
were randomized to receive 0.625 mg/d of 
conjugated equine estrogens (CEE) or match-
ing placebo. Women in the E+P trial were 
given a single tablet of CEE plus 2.5 mg/d of 
medroxyprogesterone acetate or matching 
placebo. Mean age and BMI for participants 
without hysterectomy in E+P trial were around
 
 
Figure 1: Process of study selection  
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Table 1: Characteristics of the selected studies 
 
Mattix Kramer et al., 2003 Maalouf et al., 2010 Zhao et al., 2013 
Study design Prospective cohort study Randomized clinical trials Case-control 
study 
Country United States United States China 
Study Population 43,557 27,347 197 
Natural Post- 
menopausal  
26,251 16,608 113 
Surgical Post-
menopausal 
17,306 10,739 / 
Age/years * 
(Natural) 
60.4 (5.4) 63.6 48-69 
BMI/ kg/m2 * 
(Natural) 
25.7 (4.9) 30.1 15.8-32.5 
Age/years * 
(Surgical) 
58.3 (6.6) 63.3 / 
BMI/ kg/m2* 
(Surgical) 
25.8 (4.9) 28.5 / 
Adjusted  
confounders 
age, body mass index, 
presence of hypertension, 
age at menopause, supple-
mental calcium, alcohol con-
sumption, diet, and fluid in-
take 
Age, race, diet, BMI, and 
medical history 
demographic data 
and medical his-
tory 
follow-up/years 18 5.6 / 
Type of risk RR HR OR 
* Age and BMI were expressed differently across the studies: mean, mean (SD), or range was reported 
individually. 
 
 
60.3 years old and 28.5 kg/m2 while mean age 
and BMI for participants with hysterectomy 
in the estrogen-alone trial were around 
63.6 years old and 30.1 kg/m2. All partici-
pants, including total 113 female patients with 
newly diagnosed kidney stones after meno-
pause and 84 age frequency-matched stone-
free female controls, enrolled in the case-con-
trol study conducted by Zhao et al. (2013) 
were naturally postmenopausal: The range of 
age of the study subjects was 48-69 while the 
range of BMI of the study subjects was 15.8-
32.5; Odds ratios (ORs) for associations be-
tween sex hormones indicated by the level of 
serum testosterone (T) and estradiol (E2) and 
kidney stones were estimated with logistic re-
gression models. Potential confounding ad-
justed factors slightly differed across the three 
studies, and the primarily adjusted factors 
were demographic data such as age, BMI, 
diet, and medical history. 
 
Primary analysis 
To investigate the association between 
PMH and the incident of kidney stone, we 
first stratified the results of study population 
in Mattix Kramer et al. (2003), into two kinds 
which target naturally postmenopausal and 
surgical postmenopausal women, in which 
each kind of study subjects were further di-
vided into past users and current users with a 
duration ranged from 5 to 9.9 years. For the 
two clinical trials in Maalouf et al. (2010), the 
results were separately analyzed. Fixed ef-
fects or random effects modeling were per-
formed on the extracted relative risks (Figure 
2A-B). Through heterogeneity test, we found 
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I2 is 78.22 %, suggesting a high inter- and in-
tra-study variation. Thus, a random effect 
modeling was used to perform the meta-
analysis. According to the result analyzed by 
random effect modeling (Figure 2A), there is 
no significant association between PMH and 
the risk of kidney stone formation (the pooled 
relative risk: 0.91, confidence interval (CI): 
[0.72, 1.14], p > 0.05). 
 
Subgroup analysis 
In our subgroup analysis, we aimed at in-
vestigating whether different menopause 
types influenced the association between 
PMH and the risk of nephrolithiasis. Accord-
ing to the results (Figure 3A-B), neither sig-
nificant association between PMH and risk of 
kidney stone formation was found in women 
with natural menopause or with surgical men-
opause (Naturally postmenopausal women: 
pooled RR, 0.91; 95 % CI, [0.64, 1.27]; I2 = 
82.74 %; Surgically postmenopausal women: 
pooled RR, 0.90; 95 % CI, [0.63, 1.29]; I2 = 
78.47 %).  
 
 
 
Figure 2: Forest plot of the association between postmenopausal hormone and incident kidney stone 
by random effect (RE) model (A) and fixed effect (FE) model (B). 
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Figure 3: Forest plot of the association between postmenopausal hormone (PMH) and incident kidney 
stone by different types of menopause (A, B). 
 
 
 
Sensitivity analysis 
To analyze sensitivity for each different 
stratified study, we conducted sensitivity 
analysis by omitting one stratified study and 
re-calculating pooled relative risk (Figure 4). 
Based on the result, the primary results were 
not influenced by omitting one study at a 
time. 
 
DISCUSSION 
In this meta-analysis including 7 stratified 
results and a total of 71,101 participants, we 
demonstrated that PMH is not associated with 
a statistically significant increased or de-
creased risk of nephrolithiasis. Different types 
of menopause (surgical or natural) did not 
contribute to identifying significantly in-
creased or decreased risk of kidney stone. 
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Figure 4: Sensitivity analysis of included publications (expressed by Relative Risk and 95 % CI) 
 
 
Publication bias 
To investigate whether the selected stud-
ies showing a more significant intervention 
effect than studies with null results. We plot-
ted Funnel plot with the Trim-and-Fill adjust-
ment and further conducted Fail-safe N 
method. Null study was needed to nullify the 
effect. We observed in the plot that the studies 
with higher precision tends to report higher 
relative ratio. Subsequently, we performed 
Egger’s regression test to analyze funnel plot 
asymmetry (Figure 5). Based on the results, 
we confirmed a significant publication bias (z 
= -4.3325, p < 0.0001), suggesting the size of 
the studies was associated with the reported 
risk ratio. 
 
 
 
Figure 5: Funnel Plot of log Relative Risk against standard error with trim-and-fill correction
EXCLI Journal 2017;16:986-994 – ISSN 1611-2156 
Received: March 24, 2017, accepted: June 10, 2017, published: June 30, 2017 
 
 
993 
The incidence of kidney stones is increas-
ing worldwide. Kidney stones were reported 
to affect approximately 1 in 11 people in the 
United States. The prevalence of kidney 
stones was 8.8 % (Scales et al., 2012). Kidney 
stone contributes to the development of 
chronic kidney disease (Rule et al., 2009) and 
confers threat of life of patients. The patho-
genesis of kidney stone formation remains 
elusive and was influenced by the interplay of 
genetic and environmental factors (Coe et al., 
1992; Curhan et al., 1997a; Moe, 2006). Risk 
factors such as dietary salt intake (Massey, 
2005), supplemental calcium intake (Curhan 
et al., 1997b), diabetic mellitus (Eisner et al., 
2010; Taylor et al., 2005), beverage use 
(Curhan et al., 1998), diet style (Taylor et al., 
2009), and other lifestyle factors may affect 
the risk of developing kidney stone. Medical 
management or prevention of kidney stones 
has gained great attention in recent decades.  
Menopause status is associated with in-
creased urinary calcium excretion, which may 
increase the risk for the formation of calcium-
containing kidney stones (Cappuccio et al., 
2000). The occurrence of kidney stone in sur-
gically menopausal women is higher than nat-
urally menopausal women (Mattix Kramer et 
al., 2003). Hormone use and its effects on 24-
hour urine composition have been reported in 
several laboratory and clinical studies. The re-
sults were inconsistent and sometimes contro-
versial. For instance, in Sprague-Dawley rats 
treated with ethylene glycol, estrogen was 
found to appear to inhibit stone formation by 
increasing osteopontin expression in the kid-
neys and decreasing urinary oxalate excretion 
(Yagisawa et al., 2001), suggesting a poten-
tially protective role in the incident kidney 
stone. In addition, estrogen use may involve 
in urinary excretion of kidney stone constitu-
ents and of urinary promoters. Elevated levels 
of serum testosterone and serum dihydrotes-
tosterone might be involved in increased inci-
dences of stone formation (Gupta et al., 
2016). In the clinical trials conducted by 
Maalouf et al. (2010) PMH use is associated 
with higher risk of kidney stone formation 
(Maalouf et al., 2010). One possible explana-
tion for the higher incidence of stone disease 
with hormone therapy (HT) could be through 
enhanced urinary uric acid excretion with es-
trogen use (Adamopoulos et al., 1977; 
Nicholls et al., 1973). Greater uric acid excre-
tion, in turn, could lead to heterogeneous nu-
cleation of calcium oxalate (Pak and Arnold, 
1975). 
Our study has several limitations. Due to 
limited publications reporting the association 
between PMH and formation of kidney stone, 
only 3 studies were included in this meta-
analysis. In the study of Mattix Kramer et al. 
(2003) lacking information of sample size in 
each category by different types of PMH use 
and menopause results in the inability of ana-
lyzing weights for each study. Different fol-
low-up years and specifically targeted hor-
mones may also contribute to the difficulty in 
identifying the true effect of PMH on the risk 
of kidney stone. For instance, the estrogen-
only trial used conjugated equine estrogens as 
treatment arm while E+P trial used estrogen 
plus progestin. In the study of Zhao et al. 
(2013) they focused on measuring serum es-
tradiol and testosterone levels in healthy post-
menopausal women. Besides, we did not con-
sider and separately analyze the incident kid-
ney stone based on different stone compo-
nents (calcium oxalate stones [COS]; non-cal-
cium oxalate stones [NCOS]).  
 
Acknowledgements 
None. 
 
Conflict of interest  
The authors report no conflicts of interest. 
The authors alone are responsible for the con-
tent and writing of the paper. 
 
EXCLI Journal 2017;16:986-994 – ISSN 1611-2156 
Received: March 24, 2017, accepted: June 10, 2017, published: June 30, 2017 
 
 
994 
REFERENCES 
Adamopoulos D, Vlassopoulos C, Seitanides B, Con-
toyiannis P, Vassilopoulos P. The relationship of sex 
steroids to uric acid levels in plasma and urine. Acta 
Endocrinol. 1977;85:198-208. 
Cappuccio FP, Kalaitzidis R, Duneclift S, Eastwood 
JB. Unravelling the links between calcium excretion, 
salt intake, hypertension, kidney stones and bone me-
tabolism. J Nephrol. 2000;13:169-77. 
Coe FL, Parks JH, Asplin JR. The pathogenesis and 
treatment of kidney stones. N Engl J Med. 1992;327: 
1141-52. 
Curhan GC, Willett WC, Rimm EB, Stampfer MJ. 
Family history and risk of kidney stones. J Am Soc 
Nephrol. 1997a;8:1568-73. 
Curhan GC, Willett WC, Speizer FE, Spiegelman D, 
Stampfer MJ. Comparison of dietary calcium with sup-
plemental calcium and other nutrients as factors affect-
ing the risk for kidney stones in women. Ann Intern 
Med. 1997b;126:497-504. 
Curhan GC, Willett WC, Speizer FE, Stampfer MJ. 
Beverage use and risk for kidney stones in women. Ann 
Intern Med. 1998;128:534-40. 
Dey J, Creighton A, Lindberg JS, Fuselier HA, Kok DJ, 
Cole FE, et al. Estrogen replacement increased the cit-
rate and calcium excretion rates in postmenopausal 
women with recurrent urolithiasis. J Urol. 2002; 
167:169-71. 
Eisner BH, Porten SP, Bechis SK, Stoller ML. Diabetic 
kidney stone formers excrete more oxalate and have 
lower urine ph than nondiabetic stone formers. J Urol. 
2010;183:2244-8. 
Gupta K, Gill GS, Mahajan R. Possible role of elevated 
serum testosterone in pathogenesis of renal stone for-
mation. Int J Appl Basic Med Res. 2016;6:241-4. 
Iguchi M, Takamura C, Umekawa T, Kurita T, Kohri 
K. Inhibitory effects of female sex hormones on uri-
nary stone formation in rats. Kidney Int. 1999;56:479-
85. 
Maalouf NM, Sato AH, Welch BJ, Howard BV, 
Cochrane BB, Sakhaee K, et al. Postmenopausal hor-
mone use and the risk of nephrolithiasis: results from 
the Women's Health Initiative hormone therapy trials. 
Arch Intern Med. 2010;170:1678-85. 
Massey LK. Effect of dietary salt intake on circadian 
calcium metabolism, bone turnover, and calcium oxa-
late kidney stone risk in postmenopausal women. Nutr 
Res. 2005;25:891-903. 
Mattix Kramer HJ, Grodstein F, Stampfer MJ, Curhan 
GC. Menopause and postmenopausal hormone use and 
risk of incident kidney stones. J Am Soc Nephrol. 
2003;14:1272-7. 
Moe OW. Kidney stones: pathophysiology and medi-
cal management. Lancet. 2006;367:333-44. 
Nicholls A, Snaith ML, Scott JT. Effect of oestrogen 
therapy on plasma and urinary levels of uric acid. Br 
Med J. 1973;1:449-51. 
Novak TE, Lakshmanan Y, Trock BJ, Gearhart JP, 
Matlaga BR. Sex prevalence of pediatric kidney stone 
disease in the United States: an epidemiologic investi-
gation. Urology. 2009;74:104-7. 
Pak CY, Arnold LH. Heterogeneous nucleation of cal-
cium oxalate by seeds of monosodium urate. Proc Soc 
Exp Biol Med. 1975;149:930-2. 
Rule AD, Bergstralh EJ, Melton LJ, Li X, Weaver AL, 
Lieske JC. Kidney stones and the risk for chronic kid-
ney disease. Clin J Am Soc Nephrol. 2009;4:804-11. 
Scales CD, Smith AC, Hanley JM, Saigal CS, Project 
UDiA. Prevalence of kidney stones in the United 
States. Eur Urol. 2012;62:160-5. 
Taylor EN, Stampfer MJ, Curhan GC. Diabetes melli-
tus and the risk of nephrolithiasis. Kidney Int. 2005; 
68:1230-5. 
Taylor EN, Fung TT, Curhan GC. DASH-style diet as-
sociates with reduced risk for kidney stones. J Am Soc 
Nephrol. 2009;20:2253-9. 
Yagisawa T, Ito F, Osaka Y, Amano H, Kobayashi C, 
Toma H. The influence of sex hormones on renal oste-
opontin expression and urinary constituents in experi-
mental urolithiasis. J Urol. 2001;166:1078-82. 
Zhao Z, Mai Z, Ou L, Duan X, Zeng G. Serum estradiol 
and testosterone levels in kidney stones disease with 
and without calcium oxalate components in naturally 
postmenopausal women. PLoS One. 2013;8:e75513. 
 
 
